Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7338721 | 1.00 | ARG1 (0.35) | ARG1ARG2NPSR1FFAR3 | |
| SCHEMBL28625670 | 0.89 | — | — | |
| SCHEMBL27609068 | 0.80 | NPSR1 (0.32) | ARG1ARG2NPSR1 | |
| SCHEMBL7348888 | 0.79 | ARG1 (0.31) | ARG1ARG2 | |
| SCHEMBL3824577 | 0.78 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL6975551 | 0.78 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL7340984 | 0.78 | ARG1 (0.36) | ARG1ARG2 | |
| SCHEMBL11386528 | 0.75 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL11395554 | 0.75 | ARG1 (0.31) | ARG1ARG2 | |
| SCHEMBL2339284 | 0.75 | TSHR (0.36) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4482725-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1984-11-13 | — | — | US | claimed |
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-10 | — | — | US | disclosed |
| US-20220227786-A1 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-21 | — | — | US | disclosed |
| US-6403612-B2 | UREA CONTAINING COMPOUNDS INHIBIT THE AGGREGATION OF BLOOD PLATELETS; NONTOXIC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| US-20010044454-A1 | Thrombin receptor antagonists | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| EP-0676410-B1 | Bile acids derivatives useful in the therapy of the biliary calculosis from cholesterol and of the pathologies caused by cholestasis | ALFA WASSERMANN SPA (IT) | 1997-12-03 | — | — | EP | disclosed |
| US-5639744-A | FOR TREATING DISORDERS OF THE GALLBLADDER, LIVER OR BILE DUCTS | ALFA WASSERMANN S.P.A. (IT) | 1997-06-17 | — | — | US | disclosed |
| EP-0676410-A2 | Bile acids derivatives useful in the therapy of the biliary calculosis from cholesterol and of the pathologies caused by cholestasis | ALFA WASSERMANN S.p.A. (IT) | 1995-10-11 | — | — | EP | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0053902-B1 | PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | E.R. Squibb & Sons, Inc. (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4482725-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1984-11-13 | — | — | US | disclosed |
| US-4337201-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0053902-A1 | Phosphinylalkanoyl substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-16 | — | — | EP | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4221912-A | Dithio derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4217458-A | Acylmercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4198515-A | Mercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | ARG1 4237/4885ARG2 3759/4885NPSR1 4672/4885 |
| US-20010044454-A1 | Thrombin receptor antagonists | F2R, TBXA2R, PTAFR | ARG1 1150/4885ARG2 2340/4885NPSR1 48/4885 |
| US-20220227786-A1 | Spiro Bicyclic Inhibitors Of Menin-MLL Interaction | BMI1, MLLT1, MEN1 | ARG1 4237/4885ARG2 3759/4885NPSR1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.